Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical data for PHST001, an anti-CD24 antibody ...
1 Day MA 0.00% DJIA -0.61% S&P Mid Cap 400 0.29% Basic Materials/Resources 0.26% ...
1 Day MB 19.50% DJIA -0.90% Russell 2K -1.63% Media/Entertainment -0.51% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback